Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. with Recent Share Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through recent purchases of common stock.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has reported changes in their beneficial ownership of Zymeworks Inc. stock.
• On January 8, 2025, they acquired 21,021 shares of common stock at a price of $14.073 per share.
• Following this, on January 10, 2025, they purchased an additional 204,098 shares at $13.126 per share.
• These transactions increased their total indirect holdings to 15,411,078 shares.
• The purchases were made by the Qualified Fund, with 19,752 shares on January 8th and 191,791 shares on January 10th.
• After these transactions, the Qualified Fund held 14,442,664 shares of Zymeworks' common stock.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment due to the increased investment by a major shareholder, suggesting confidence in the company's prospects. However, it is a routine filing, so the sentiment is not overly strong.

Positives

• EcoR1 Capital's increased investment signals confidence in Zymeworks Inc.
• The purchases demonstrate a commitment to the company's future.

Risks

• The document does not explicitly state any risks, but the increased ownership could lead to greater influence by EcoR1 Capital.

Management Comments

• The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.
• The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership, which is common in the biotech industry where institutional investors often hold significant stakes.

Comparison to Industry Standards

• Similar filings are common among biotech companies with significant institutional ownership, such as those held by venture capital firms or hedge funds.
• The size of the transactions is not unusual for a company of Zymeworks' market capitalization.
• Other companies with similar ownership structures include companies like BioMarin Pharmaceutical Inc. and Incyte Corporation, where large institutional investors frequently adjust their positions.

Stakeholder Impact

• The increased stake by EcoR1 Capital could be viewed positively by shareholders, potentially increasing confidence in the company.
• The transactions may have a minor impact on the stock price.

Key Dates

Keywords

Zymeworks, EcoR1 Capital, share purchase, beneficial ownership, stock acquisition, investment, ZYME